AAAAAA

   
Results: 1-14 |
Results: 14
FLOXURIDINE (FUDR) PLUS INTERFERON ALPHA-2A (IFN 2A) PLUS 13-CIS-RETINOIC ACID (CRA) IN METASTATIC RENAL-CELL CARCINOMA (MRCC)
Authors: CIANCI C ANTONUZZO A FALCONE A GALLI L RICCI S SACCO C CARTEI G BERTUCCELLI M TAVIANI R CONTE PF
Citation: C. Cianci et al., FLOXURIDINE (FUDR) PLUS INTERFERON ALPHA-2A (IFN 2A) PLUS 13-CIS-RETINOIC ACID (CRA) IN METASTATIC RENAL-CELL CARCINOMA (MRCC), Annals of oncology, 9, 1998, pp. 300-300
GEMCITABINE MONOTHERAPY IN THE ELDERLY PATIENT WITH ADVANCED NONSMALLCELL LUNG-CANCER
Authors: ANTONUZZO A GALLI L RICCI S TIBALDI C PETRUZZELLI S TAVANTI L FIORETTO ML ALGERI R ANDREI A CONTE PF
Citation: A. Antonuzzo et al., GEMCITABINE MONOTHERAPY IN THE ELDERLY PATIENT WITH ADVANCED NONSMALLCELL LUNG-CANCER, Annals of oncology, 9, 1998, pp. 427-427
MULTICENTER RANDOMIZED PHASE-II STUDY WITH GEMCITABINE (GEM) PLUS CISPLATIN (CDDP) IN PATIENTS WITH STAGE IIIB-IV NSCLC
Authors: RICCI S ANTONUZZO A GALLI L ALGERI R BONIFAZI V ANDREI A PETRUZZELLI S DUPRE C PEGNA AL CONTE PF
Citation: S. Ricci et al., MULTICENTER RANDOMIZED PHASE-II STUDY WITH GEMCITABINE (GEM) PLUS CISPLATIN (CDDP) IN PATIENTS WITH STAGE IIIB-IV NSCLC, Annals of oncology, 9, 1998, pp. 456-456
THE NEW LONG-ACTING SOMATOSTATIN ANALOG LANREOTIDE IN NEUROENDOCRINE TUMORS (NETS)
Authors: GALLI L RICCI S ANTONUZZO A BENGALA C CONTE PF
Citation: L. Galli et al., THE NEW LONG-ACTING SOMATOSTATIN ANALOG LANREOTIDE IN NEUROENDOCRINE TUMORS (NETS), Annals of oncology, 9, 1998, pp. 625-625
PRELIMINARY-RESULTS OF A MULTICENTER PHASE-II STUDY WITH GEMCITABINE MONOTHERAPY IN THE ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC)
Authors: TIBALDI C RICCI S BONIFAZI F FIORETTO ML BERTUCCELLI M PETRUZZELLI S GALLI L ANTONUZZO A ANDREI A TAVANTI L GIALLOMBARDO A CHIAVACCI A PEGNA AL CONTE PF
Citation: C. Tibaldi et al., PRELIMINARY-RESULTS OF A MULTICENTER PHASE-II STUDY WITH GEMCITABINE MONOTHERAPY IN THE ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC), Annals of oncology, 9, 1998, pp. 143-143
LONG-ACTING LANREOTIDE IN THE TREATMENT OF NEUROENDOCRINE TUMORS (NETS)
Authors: ANTONUZZO A RICCI S GALLI L CONTE PF
Citation: A. Antonuzzo et al., LONG-ACTING LANREOTIDE IN THE TREATMENT OF NEUROENDOCRINE TUMORS (NETS), Annals of oncology, 9, 1998, pp. 670-670
DOUBLE-BLIND, DOSE-FINDING STUDY OF 4 INTRAVENOUS DOSES OF DEXAMETHASONE IN THE PREVENTION OF CISPLATIN-INDUCED ACUTE EMESIS
Authors: ROILA F BALLATORI E DEANGELIS V TONATO M DELFAVERO A CICCARESE G BASURTO C CICCARESE G PALLADINO MA PORROZZI S PICCIAFUOCO M CONTU A OLMEO N PAZZOLA A PILO L TATEO S CHIAPPARINI I MORANA S LUCCHINO S RICCI S ANTONUZZO A ALLEGRINI G GALLI L CONTE PF MASSIDDA B IONTA MT SCANU A MURRU R PICECE V CIRILLO M MAGAROTTO R NUZZO A LAUDADIO L SABLONE MG LOCATELLI MC DANTONA A LUPORINI G SCAGLIOTTI G SELVAGGI G MATTEI A FAVALLI G GAMBINO A FAVA S GRIMI E SCARFONE G BOLIS MC ALESSANDRONI P CATALANO G BONI C MORETTI G CORTESI E MARTELLI O ANTIMI M BELLINI V BUZZI E BRUGIA M GRECCHI M CLERICO M MONTINARI F DONATI D SANSONI E
Citation: F. Roila et al., DOUBLE-BLIND, DOSE-FINDING STUDY OF 4 INTRAVENOUS DOSES OF DEXAMETHASONE IN THE PREVENTION OF CISPLATIN-INDUCED ACUTE EMESIS, Journal of clinical oncology, 16(9), 1998, pp. 2937-2942
ACUTE AND DELAYED EMESIS IN PATIENTS WITH SOLID TUMORS UNDERGOING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT (ASCS)
Authors: RICCI S ALLEGRINI G ANTONUZZO A MARCHETTI V GINI S GALLI L MACCA A BENGALA C PAZZAGLI I CONTE PF
Citation: S. Ricci et al., ACUTE AND DELAYED EMESIS IN PATIENTS WITH SOLID TUMORS UNDERGOING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT (ASCS), European journal of cancer, 33, 1997, pp. 251-251
MAXIMUM TOLERABLE DOSES OF INTRAVENOUS ZIDOVUDINE IN COMBINATION WITH5-FLUOROURACIL AND LEUCOVORIN IN METASTATIC COLORECTAL-CANCER PATIENTS - CLINICAL-EVIDENCE OF SIGNIFICANT ANTITUMOR-ACTIVITY AND ENHANCEMENT OF ZIDOVUDINE-INDUCED DNA SINGLE-STRAND BREAKS IN PERIPHERAL NUCLEARBLOOD-CELLS
Authors: FALCONE A LENCIONI M BRUNETTI I PFANNER E ALLEGRINI G ANTONUZZO A ANDREUCCETTI M MALVALDI G DANESI R DELTACCA M CONTE PF
Citation: A. Falcone et al., MAXIMUM TOLERABLE DOSES OF INTRAVENOUS ZIDOVUDINE IN COMBINATION WITH5-FLUOROURACIL AND LEUCOVORIN IN METASTATIC COLORECTAL-CANCER PATIENTS - CLINICAL-EVIDENCE OF SIGNIFICANT ANTITUMOR-ACTIVITY AND ENHANCEMENT OF ZIDOVUDINE-INDUCED DNA SINGLE-STRAND BREAKS IN PERIPHERAL NUCLEARBLOOD-CELLS, Annals of oncology, 8(6), 1997, pp. 539-545
DELAYED EMESIS INDUCED BY MODERATELY EMETOGENIC CHEMOTHERAPY - DO WE NEED TO TREAT ALL PATIENTS
Authors: BALLATORI E ROILA F DEANGELIS V RIVA E BARBIERI P DELFAVERO A BASURTO C CICCARESE G PALLADINO MA MOSCONI AM ANASTASI P PICCIAFUOCO M CAMPORA E CHIARA S COGNETTI F FERRARESI V FABI A TONACHELLA R CIRULLI S SABBATINI R FEDERICO M TRASSOLDATI A SILINGARDI V DONATI D MAESTRI A MALACARNE P RICCI S ANTONUZZO A ALLEGRINI G CONTE PF SALVATI F NUNZIATI F ANTILLI A CATALANO G CASCINU S DICOSTANZO F TAGLIAVENTI M ZANIBONI A MERIGGI F CORTESI E RAMPONI S LOCATELLI MC SANTORO A ZUCCHINELLI P MANTELLINI E FERRETTI G BONI C MORETTI G SCAGLIOTTI G DANIELE O LISSONI A TATEO S
Citation: E. Ballatori et al., DELAYED EMESIS INDUCED BY MODERATELY EMETOGENIC CHEMOTHERAPY - DO WE NEED TO TREAT ALL PATIENTS, Annals of oncology, 8(6), 1997, pp. 561-567
AZIDOTHYMIDINE IN COMBINATION WITH 5-FLUOROURACIL IN HUMAN COLORECTALCELL-LINES - IN-VITRO SYNERGISTIC CYTOTOXICITY AND DNA-INDUCED STRAND-BREAKS
Authors: ANDREUCCETTI M ALLEGRINI G ANTONUZZO A MALVALDI G CONTE PF DANESI R DELTACCA M FALCONE A
Citation: M. Andreuccetti et al., AZIDOTHYMIDINE IN COMBINATION WITH 5-FLUOROURACIL IN HUMAN COLORECTALCELL-LINES - IN-VITRO SYNERGISTIC CYTOTOXICITY AND DNA-INDUCED STRAND-BREAKS, European journal of cancer, 32A(7), 1996, pp. 1219-1226
BRCA1 GENE MUTATION CARRIER ANALYSIS IN FAMILIAL BREAST-CANCER PATIENTS
Authors: CALIGO MA GHIMENTI C RICCI S ANTONUZZO A MARCHETTI V ALLEGRINI G CIPOLLINI G MARESI MP OLSEN R MCCLURE M FRYE C SHATTUCKEIDENS D NEUHAUSEN S SKOLNICK M CONTE PF BEVILACQUA G
Citation: Ma. Caligo et al., BRCA1 GENE MUTATION CARRIER ANALYSIS IN FAMILIAL BREAST-CANCER PATIENTS, European journal of cancer, 31A, 1995, pp. 449-449
ONDANSETRON VERSUS GRANISETRON, BOTH COMBINED WITH DEXAMETHASONE, IN THE PREVENTION OF CISPLATIN-INDUCED EMESIS
Authors: BASURTO C CICCARESE G PALLADINO MA PICCIAFUOCO M RICCI S ANTONUZZO A ALLEGRINI G CONTE PF COGNETTI F CIRULLI S COLELLA E MILELLA M SAVARESE A STANI S CONTU A OLMEO N PIRO S PIRAS M PILO L PILO P NUZZO A URSINI LA TARABORRELLI M MELENA S BASILICO L BUZZI F BRUGIA M TRIPPA F DELRIO S TAGLIAVENTI M PICECE V CASSANDRINI P CIRILLO M MAGAROTTO R RECALDIN E CLERICO M BARTETTO O MORANDINI MP BAINOTTI L BONI C MORETTI G SAVOLDI L TATEO S CHIAPPARINI I ZARA C CATALANO G CASCINU S ALESSANDRONI P MASSIDDA B IONTA MT PEDDITZI E MONTINARI F CASARTELLI C MANDELLI D ROTONDO SG LELLI G CILENTI G MORRITTI M PUSCEDDU G SALARIS G PRESTI ML FAVALLI G GAMBINO A RAVELLI V CORTESI E GIOACCHINI N OLIVA A DAZZI C MONTANARI L CRUCIANI G DEMARINIS F SCARFONE G BOLIS MC SCAGLIOTTI G SELVAGGI G DONATI D MALACARNE P SANTORO A PARRA HS LOCATELLI MC LUPORINI G SANSONI E MATERA G FAVA C
Citation: C. Basurto et al., ONDANSETRON VERSUS GRANISETRON, BOTH COMBINED WITH DEXAMETHASONE, IN THE PREVENTION OF CISPLATIN-INDUCED EMESIS, Annals of oncology, 6(8), 1995, pp. 805-810
PERSISTENCE OF EFFICACY OF 3 ANTIEMETIC REGIMENS AND PROGNOSTIC FACTORS IN PATIENTS UNDERGOING MODERATELY EMETOGENIC CHEMOTHERAPY
Authors: BALLATORI E ROILA F DEANGELIS V TONATO M RIVA E BARBIERI P DELFAVERO A BASURTO C CICCARESE G PALLADINO MA MOSCONI AM ANASTASI P PICCIAFUOCO M CAMPORA E CHIARA S COGNETTI F FERRARESI V FABI A COLELLA E CIRULLI S SABBATINI R FEDERICO M BARBIERI F SILINGARDI V ANNA S DONATI D MAESTRI A MALACARNE P RICCI S ANTONUZZO A CONTE PF SALVATI F NUNZIATI F ANTILLI A CATALANO G CASCINU S DICOSTANZO F TAGLIAVENTI M ZANIBONI Z MERIGGI F CORTESI E CALABRO F CARLO S LUPORINI G DANTONA A SANTORO A GIACOBONE A MANTELLINI E FERRETTI G BONI C MORETTI G SCAGLIOTTI G DANIELE O LISSONI A TATEO S
Citation: E. Ballatori et al., PERSISTENCE OF EFFICACY OF 3 ANTIEMETIC REGIMENS AND PROGNOSTIC FACTORS IN PATIENTS UNDERGOING MODERATELY EMETOGENIC CHEMOTHERAPY, Journal of clinical oncology, 13(9), 1995, pp. 2417-2426
Risultati: 1-14 |